CO2022016537A2 - Inactivated vaccine for sars-cov-2 and preparation thereof - Google Patents

Inactivated vaccine for sars-cov-2 and preparation thereof

Info

Publication number
CO2022016537A2
CO2022016537A2 CONC2022/0016537A CO2022016537A CO2022016537A2 CO 2022016537 A2 CO2022016537 A2 CO 2022016537A2 CO 2022016537 A CO2022016537 A CO 2022016537A CO 2022016537 A2 CO2022016537 A2 CO 2022016537A2
Authority
CO
Colombia
Prior art keywords
cov
sars
preparation
inactivated vaccine
vaccine
Prior art date
Application number
CONC2022/0016537A
Other languages
Spanish (es)
Inventor
Qiang Gao
Lin Wang
Yurong Li
Zhidong Yao
Jiling Shang
Yanhui Yin
Yajing Li
Zhe Lv
Zhuofa Li
Cien Shan
Xiaoqin Ge
Zhiwei Wang
Yangqi Sun
Zengbing Guo
Feng Xue
Original Assignee
Sinovac Res & Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202010307512.8A external-priority patent/CN113521273A/en
Application filed by Sinovac Res & Development Co Ltd filed Critical Sinovac Res & Development Co Ltd
Publication of CO2022016537A2 publication Critical patent/CO2022016537A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C12N2770/20063—Methods of inactivation or attenuation by chemical treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporciona una vacuna inactivada para SARS-Cov-2, y la preparación de la misma. También se proporciona un método para el tratamiento o prevención o inmunización contra enfermedades asociadas con la infección por virus SARS-Cov-2, que comprende administrar a un sujeto una composición farmacéutica o una vacuna que comprende una cantidad farmacéuticamente eficaz del virus SARS-Cov-2 inactivado y un vehículo farmacéuticamente aceptable.An inactivated vaccine for SARS-Cov-2, and the preparation thereof are provided. Also provided is a method for the treatment or prevention or immunization against diseases associated with SARS-Cov-2 virus infection, which comprises administering to a subject a pharmaceutical composition or a vaccine comprising a pharmaceutically effective amount of the SARS-Cov-2 virus. 2 inactivated and a pharmaceutically acceptable carrier.

CONC2022/0016537A 2020-04-17 2022-11-16 Inactivated vaccine for sars-cov-2 and preparation thereof CO2022016537A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010307512.8A CN113521273A (en) 2020-04-17 2020-04-17 Novel crown COVID-19 inactivated vaccine using composite adjuvant containing CpG oligodeoxynucleotide
CN2020086892 2020-04-25
PCT/CN2021/087957 WO2021209060A1 (en) 2020-04-17 2021-04-17 Inactivated vaccine for sars-cov-2 and preparation thereof

Publications (1)

Publication Number Publication Date
CO2022016537A2 true CO2022016537A2 (en) 2023-02-27

Family

ID=78083525

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0016537A CO2022016537A2 (en) 2020-04-17 2022-11-16 Inactivated vaccine for sars-cov-2 and preparation thereof

Country Status (5)

Country Link
CN (1) CN115836124A (en)
BR (1) BR112022019601A2 (en)
CL (1) CL2022002832A1 (en)
CO (1) CO2022016537A2 (en)
WO (1) WO2021209060A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1829736A (en) * 2003-04-10 2006-09-06 希龙公司 The severe acute respiratory syndrome coronavirus
CN111662881B (en) * 2020-06-12 2021-06-18 北京生物制品研究所有限责任公司 Novel coronavirus Vero cell inactivated vaccine virus liquid and production method thereof
CN111569058B (en) * 2020-06-18 2021-08-13 武汉生物制品研究所有限责任公司 SARS-CoV-2 inactivated vaccine and its preparation method

Also Published As

Publication number Publication date
CN115836124A (en) 2023-03-21
CL2022002832A1 (en) 2023-04-28
WO2021209060A1 (en) 2021-10-21
BR112022019601A2 (en) 2022-11-16

Similar Documents

Publication Publication Date Title
AR108829A1 (en) VACCINE AGAINST INFECTIOUS BRONCHITIS VIRUS
GT200200138A (en) VACCINATION IN ONE DOSE WITH MYCOPLASMA HYOPNEUMONIAE
ES2570401T3 (en) Methods of treatment using single doses of oritavancin
CO2023003242A2 (en) Vaccine against coronavirus and procedure for its preparation
AR119159A1 (en) ANGIOEDEMA TREATMENTS
MX2022006742A (en) Use and pharmaceutical composition of phenylisoxazolyl methylene-naphthalene-ether derivatives.
CL2021002582A1 (en) Vaccines against porcine circovirus type 3 (pcv3), their production and uses
BR112023021654A2 (en) VIRUS VACCINE
DE60331412D1 (en) HIV vaccine and method of administration
MX2023003784A (en) Sars-cov-2 protein-derived peptide and vaccine containing same.
BR112023000220A2 (en) LONG-ACTION FORMULATIONS
MX2021010834A (en) Compound and method for the prevention of transmission of influenza virus.
MX2020006662A (en) INTRADERMAL COMBINATION VACCINE AGAINST <i>MYCOPLASMA</i> AND PORCINE CIRCOVIRUS.
CO2022016537A2 (en) Inactivated vaccine for sars-cov-2 and preparation thereof
CO2023014650A2 (en) Dosage and administration of recombinant l-asparaginase
CO2022007006A2 (en) Triple vaccine against avibacterium paragallinarum and avian encephalomyelitis virus and fowlpox virus
CL2021003312A1 (en) Composition comprising pridopidine and an analog thereof for the treatment of huntington's disease and its symptoms.
AR127533A1 (en) SARS-CoV-2 INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS
MX2022013722A (en) Cysteamine for the treatment of sars-cov-2 infection.
CL2022000095A1 (en) Pharmaceutical compositions resistant to the discharge of doses that comprise venirunad
BR112022007474A2 (en) CHIKUNGUNYA VIRUS-LIKE PARTICLE VACCINE AND METHODS OF USE THEREOF
WO2022150719A3 (en) Antigenic composition(s) and method(s) against porphyromonas gingivalis for the prevention and/or treatment of infection and/or diseases
BR112021026839A2 (en) Pharmaceutical compositions for treating and preventing an influenza virus infectious disease
EA202100185A2 (en) VACCINE AND METHOD FOR INCREASING IMMUNOGENICITY AND SPECIFIC ACTIVITY OF INFECTION PREVENTION MEANS
AR122161A1 (en) PROCEDURE FOR THE TREATMENT OF VIRUS INFECTION WITH IVIG AND CONVALESCENT PLASMA